Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer

Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin-paclitaxel regimen over cispla...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of gynecological cancer Vol. 13 Suppl 2; p. 144
Main Authors:	Piccart, M J, Bertelsen, K, Stuart, G, Cassidy, J, Mangioni, C, Simonsen, E, James, K, Kaye, S, Vergote, I, Blom, R, Grimshaw, R, Atkinson, R, Swenerton, K, Trope, C, Nardi, M, Kaern, J, Tumolo, S, Timmers, P, Roy, J-A, Lhoas, F, Lidvall, B, Bacon, M, Birt, A, Andersen, J, Zee, B, Paul, J, Pecorelli, S, Baron, B, McGuire, W
Format:	Journal Article
Language:	English
Published:	England 01-11-2003
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Canada Cisplatin - administration & dosage Cyclophosphamide - administration & dosage Europe Female Follow-Up Studies Humans Longitudinal Studies Neoplasm Staging Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Paclitaxel - administration & dosage Randomized Controlled Trials as Topic Survival Analysis Canada Europe
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin-paclitaxel regimen over cisplatin-cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.
ISSN:	1048-891X
DOI:	10.1111/j.1525-1438.2003.13357.x